Genelux Corporation plans a public offering of common stock on Nasdaq (GNLX). Underwriter may have option for 15% more. Market conditions can affect completion.
Genelux Corporation, a late clinical-stage immuno-oncology company based in Westlake Village, California, has announced the commencement of a proposed underwritten public offering of its common stock on Jan. 7, 2026. The company, listed as GNLX on Nasdaq, plans to offer all shares in the offering and expects to provide the underwriter with a 30-day option to acquire up to an additional 15% of the shares sold. This offering is subject to market conditions and standard closing procedures, with uncertainties regarding its completion, size, and terms.
Source: Unusual Whales The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments